Anabolic Skeletal Agents for Osteoporosis

描述（由申请人提供）： 骨质疏松症是一个巨大的和不断增长的公共卫生问题。它导致了巨大的社会负担的骨痛，骨折，死亡率和生活质量的降低。它影响男性和女性，并且随着人口老龄化，发病率正在增加。骨质疏松症在美国每年的成本仅在女性中就在300亿美元的范围内。骨质疏松症可以是原发性的（绝经后和老年性骨质疏松症），也可以是继发性的（例如在患有风湿性疾病和肺气肿的糖皮质激素治疗患者中）。迄今为止，治疗的主要支柱是营养（钙和维生素D）和通过使用所谓的“抗再吸收”药物家族（例如雌激素、选择性雌激素受体调节剂、双膦酸盐和降钙素）阻断骨细胞骨再吸收来防止进一步的骨损失。在妇女健康倡议的中期结果发布后，最近雌激素的使用明显减少，使美国数百万妇女对骨质疏松症“不受保护”。 在过去的一年里，FDA批准了甲状旁腺激素，这是一类新的骨骼合成代谢药物中的第一种有效药物。这一事件，以及对成骨细胞骨形成的理解的快速和广泛的进展，以及对合成代谢骨骼剂的无数新的潜在信号分子和转录靶点的鉴定的爆炸，彻底改变了骨质疏松症治疗领域。 美国骨与矿物质研究协会是世界上最大的和首屈一指的研究和促进与骨骼有关的疾病的基础和临床研究的协会。过去，我们与NIH在会议开发方面进行了有效的合作。上述考虑清楚地表明，这是高级思想领袖，中期职业研究者和年轻研究者与NIH研究所工作人员在小型会议中会面的时候，以审查该领域的现状，集体思考该领域应该移动的方向，并尝试优先考虑未来临床和基础研究应该关注的领域。 因此，本提案的目的是在NIH Lister Hill中心召开一次会议，重点讨论Skeleton合成代谢药物和骨质疏松症治疗的进展。

DESCRIPTION (provided by applicant): Osteoporosis is an enormous and continually growing public health problem. It leads to a large societal burden of bone pain, skeletal fracture, mortality and reduction in the quality of life. It affects men and women, and is increasing in incidence as the population ages. The annual cost of osteoporosis in the US is in the range of $30 billion in women alone. Osteoporosis can be primary (post-menopausal and senile osteoporosis) or can be secondary (for example in patients with rheumatic disease and emphysema on glucocorticoid therapy). To date, the mainstays of therapy have been directed at nutrition (calcium and vitamin D) and at preventing further bone loss through the blockade of osteoclastic bone resorption using a family of so called "anti-resorptive" drugs such as estrogen, selective estrogen receptor modulators, bisphosphonates and calcitonin. The recent and marked reduction in the use of estrogens following the release of the interim results of the Women's Health Initiative has left millions of women in the US "unprotected" against osteoporosis. In the past year, the FDA has approved parathyroid hormone, the first effective drug in a new class of skeletal anabolic agents. This event, together with rapid and extensive advances in the understanding of osteoblastic bone formation, with the explosion in identification of a myriad of new potential signaling molecules and transcriptional targets for anabolic skeletal agents, has revolutionized the field of osteoporosis therapy. The American Society for Bone and Mineral Research is the world's largest and premier society for the study and advancement of basic and clinical research in disorders relating to the skeleton. We have worked effectively in the past with the NIH in conference development. The considerations described above make it very clear that this is the time for senior thought leaders, mid-career investigators, and young investigators to meet in a small meeting setting, with NIH Institute staff, to review the current status of the field, to think collectively about the direction(s) in which the field should move, and to try to prioritize areas in which future clinical and basic research should be focused. Thus, the Aim of this proposal is to develop a meeting at the NIH Lister Hill center focused on advances in Skeletal Anabolic Agents and the Treatment of Osteoporosis.